Chimerix, Inc. (NASDAQ:CMRX) Short Interest Update

Chimerix, Inc. (NASDAQ:CMRX) was the recipient of a large decrease in short interest in October. As of October 31st, there was short interest totalling 1,520,000 shares, a decrease of 12.6% from the October 15th total of 1,740,000 shares. Based on an average daily trading volume, of 460,100 shares, the days-to-cover ratio is currently 3.3 days. Currently, 1.9% of the shares of the stock are short sold.

Chimerix Trading Down 4.3 %

Shares of Chimerix stock traded down $0.04 during trading hours on Friday, reaching $0.86. 689,133 shares of the company’s stock were exchanged, compared to its average volume of 250,829. Chimerix has a 52-week low of $0.75 and a 52-week high of $1.30. The company has a fifty day moving average of $0.90 and a 200-day moving average of $0.91. The firm has a market capitalization of $77.34 million, a price-to-earnings ratio of -0.91 and a beta of 1.13.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently weighed in on the company. StockNews.com raised Chimerix from a “sell” rating to a “hold” rating in a report on Wednesday, August 21st. HC Wainwright reissued a “buy” rating and issued a $11.00 target price on shares of Chimerix in a research note on Monday, November 11th. Finally, Wedbush reaffirmed an “outperform” rating and set a $6.00 price target on shares of Chimerix in a research note on Thursday, November 7th.

Hedge Funds Weigh In On Chimerix

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Connor Clark & Lunn Investment Management Ltd. lifted its stake in shares of Chimerix by 66.8% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 344,712 shares of the biopharmaceutical company’s stock valued at $321,000 after purchasing an additional 138,098 shares in the last quarter. Valeo Financial Advisors LLC lifted its position in Chimerix by 566.9% during the third quarter. Valeo Financial Advisors LLC now owns 81,766 shares of the biopharmaceutical company’s stock valued at $76,000 after buying an additional 69,505 shares in the last quarter. Marshall Wace LLP purchased a new stake in Chimerix during the second quarter worth approximately $137,000. Acadian Asset Management LLC raised its stake in shares of Chimerix by 15.5% in the 1st quarter. Acadian Asset Management LLC now owns 2,174,813 shares of the biopharmaceutical company’s stock valued at $2,304,000 after acquiring an additional 291,981 shares during the period. Finally, Koshinski Asset Management Inc. acquired a new position in shares of Chimerix during the 1st quarter valued at $42,000. Institutional investors and hedge funds own 45.42% of the company’s stock.

About Chimerix

Chimerix, Inc, a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors.